NCT06834282 - CER-1236 in Patients With Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2029

Conditions

AMLAcute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

CER-1236

an autologous chimeric engulfment receptor T-cell

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

DRUG

Mesna

Chemoprotectant

Trial Locations (3)

RECRUITING

Sarah Cannon Research Insitute, Nashville

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

RECRUITING

Colorado Blood Cancer Institute, Denver